• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善试验样本量计算的新指南:引出目标差异。

New guidance to improve sample size calculations for trials: eliciting the target difference.

作者信息

Bell Melanie L

机构信息

Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, 85724, USA.

出版信息

Trials. 2018 Nov 5;19(1):605. doi: 10.1186/s13063-018-2894-y.

DOI:10.1186/s13063-018-2894-y
PMID:30396364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6219024/
Abstract

BACKGROUND

Sample size calculations are central to the design of health research trials. To ensure that the trial provides good evidence to answer the trial's research question, the target effect size (difference in means or proportions, odds ratio, relative risk or hazard ratio between trial arms) must be specified under the conventional approach to determining the sample size. However, until now, there has not been comprehensive guidance on how to specify this effect.

MAIN TEXT

This is a commentary on a collection of papers from two important projects, DELTA (Difference ELicitation in TriAls) and DELTA that aim to provide evidence-based guidance on systematically determining the target effect size, or difference and the resultant sample sizes for trials. In addition to surveying methods that researchers are using in practice, the research team met with various experts (statisticians, methodologists, clinicians and funders); reviewed guidelines from funding agencies; and reviewed recent methodological literature. The DELTA guidance stresses specifying important and realistic differences, and undertaking sensitivity analyses in calculating sample sizes. It gives recommendations on how to find appropriate differences, conduct the sample size calculation(s) and how to report these in grant applications, protocols and manuscripts. It is hoped that this will contribute not only to better powered studies, but better reporting and reproducibility and thinking about what a trial should be designed to achieve.

CONCLUSIONS

The DELTA researchers have developed a set of comprehensive guidance documents that are welcome and will almost certainly improve the way that trials are designed and reported.

摘要

背景

样本量计算是健康研究试验设计的核心内容。为确保试验能提供充分证据以回答试验的研究问题,在传统的样本量确定方法中,必须明确目标效应量(试验组之间均值或比例的差异、比值比、相对风险或风险比)。然而,迄今为止,对于如何确定这个效应量尚无全面的指导。

正文

这是一篇对来自两个重要项目(DELTA,即试验中差异引出项目)的一系列论文的评论,其目的是为系统确定目标效应量、差异以及试验所需的样本量提供循证指导。除了调查研究人员在实际中使用的方法外,研究团队还与各类专家(统计学家、方法学家、临床医生和资助者)进行了会面;查阅了资助机构的指南;并回顾了近期的方法学文献。DELTA指南强调明确重要且现实的差异,并在计算样本量时进行敏感性分析。它针对如何找到合适的差异、进行样本量计算以及如何在资助申请、试验方案和论文中报告这些内容给出了建议。希望这不仅有助于开展效能更高的研究,还能促进更好的报告、可重复性以及对试验应设计达到何种目的的思考。

结论

DELTA研究人员已制定出一套全面的指导文件,这些文件很受欢迎,几乎肯定会改善试验设计和报告的方式。

相似文献

1
New guidance to improve sample size calculations for trials: eliciting the target difference.改善试验样本量计算的新指南:引出目标差异。
Trials. 2018 Nov 5;19(1):605. doi: 10.1186/s13063-018-2894-y.
2
Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA five-stage study, including a workshop.RCT 样本量计算中目标差值指定的实用帮助:DELTA 五阶段研究,包括研讨会。
Health Technol Assess. 2019 Oct;23(60):1-88. doi: 10.3310/hta23600.
3
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.评估指定随机对照试验目标差值的方法:DELTA(试验中差值确定)综述。
Health Technol Assess. 2014 May;18(28):v-vi, 1-175. doi: 10.3310/hta18280.
4
DELTA guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.关于选择目标差异以及进行和报告随机对照试验样本量计算的DELTA指南。
Trials. 2018 Nov 5;19(1):606. doi: 10.1186/s13063-018-2884-0.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA guidance.选择目标差异并进行和报告随机对照试验的样本量计算——DELTA指南的制定
Trials. 2018 Oct 10;19(1):542. doi: 10.1186/s13063-018-2887-x.
7
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
8
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA guidance protocol.为随机对照试验选择目标差异(“效应量”)——DELTA指南方案。
Trials. 2017 Jun 12;18(1):271. doi: 10.1186/s13063-017-1969-5.
9
Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic review.随机对照试验中目标差值的指定方法:试验差值 elicitation(DELTA)系统评价。
PLoS Med. 2014 May 13;11(5):e1001645. doi: 10.1371/journal.pmed.1001645. eCollection 2014 May.
10
Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers.确定随机对照试验主要结局的目标差异:给研究人员的指南。
Trials. 2015 Jan 15;16:12. doi: 10.1186/s13063-014-0526-8.

引用本文的文献

1
Protocol Development for Investigator-Sponsored Clinical Studies.研究者发起的临床研究的方案制定
Clin Transl Sci. 2025 May;18(5):e70237. doi: 10.1111/cts.70237.
2
Colchicine for the primary prevention of cardiovascular events.秋水仙碱用于心血管事件的一级预防。
Cochrane Database Syst Rev. 2025 Feb 10;2(2):CD015003. doi: 10.1002/14651858.CD015003.pub2.
3
Bioavailability as Proof to Authorize the Clinical Testing of Neurodegenerative Drugs-Protocols and Advice for the FDA to Meet the ALS Act Vision.作为授权神经退行性药物临床测试的生物利用度证明——为满足 ALS 法案愿景,向 FDA 提供的方案和建议。
Int J Mol Sci. 2024 Sep 23;25(18):10211. doi: 10.3390/ijms251810211.
4
Pilot study of paediatric regional lung function assessment via X-ray velocimetry (XV) imaging in children with normal lungs and in children with cystic fibrosis.通过X射线速度成像(XV)对肺部正常儿童和囊性纤维化儿童进行儿科区域肺功能评估的初步研究。
BMJ Open. 2024 Feb 5;14(2):e080034. doi: 10.1136/bmjopen-2023-080034.
5
Motivational Interviewing as an Intervention to Improve Antiretroviral Treatment Initiation Among People who Inject Drugs (PWID): A Pilot Study in Jakarta and Bandung, Indonesia.动机性访谈作为一种干预措施以改善注射吸毒者(PWID)的抗逆转录病毒治疗启动情况:印度尼西亚雅加达和万隆的一项试点研究
Curr Drug Res Rev. 2024;16(2):228-236. doi: 10.2174/2589977515666230531154629.
6
Feasibility and effectiveness of WhatsApp online group on breastfeeding by peer counsellors: a single-blinded, open-label pilot randomized controlled study.同伴咨询师通过 WhatsApp 在线群组进行母乳喂养的可行性和效果:一项单盲、开放标签的试点随机对照研究。
Int Breastfeed J. 2022 Dec 22;17(1):91. doi: 10.1186/s13006-022-00535-z.
7
Feasibility and Acceptability of an Online WhatsApp Support Group on Breastfeeding: Protocol for a Randomized Controlled Trial.关于母乳喂养的在线WhatsApp支持小组的可行性和可接受性:一项随机对照试验的方案
JMIR Res Protoc. 2022 Mar 9;11(3):e32338. doi: 10.2196/32338.
8
Sample size, sample size planning, and the impact of study context: systematic review and recommendations by the example of psychological depression treatment.样本量、样本量规划以及研究背景的影响:以心理抑郁治疗为例的系统综述及建议。
Psychol Med. 2021 Apr;51(6):902-908. doi: 10.1017/S003329172100129X. Epub 2021 Apr 21.
9
Feasibility, acceptability, and potential efficacy of an innovative postnatal home-based breastfeeding peer support programme in Hong Kong: a feasibility and pilot randomised controlled trial.香港一项基于家庭的产后母乳喂养同伴支持创新计划的可行性、可接受性和潜在效果:一项可行性和试点随机对照试验。
Int Breastfeed J. 2021 Apr 13;16(1):34. doi: 10.1186/s13006-021-00381-5.
10
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.适应性设计 CONSORT 扩展(ACE)声明:一份带有解释和说明指南的清单,用于报告使用适应性设计的随机试验。
BMJ. 2020 Jun 17;369:m115. doi: 10.1136/bmj.m115.

本文引用的文献

1
DELTA guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial.DELTA 指南:选择目标差值以及进行和报告随机对照试验的样本量计算。
BMJ. 2018 Nov 5;363:k3750. doi: 10.1136/bmj.k3750.
2
A study of target effect sizes in randomised controlled trials published in the Health Technology Assessment journal.一项对发表在《卫生技术评估》杂志上的随机对照试验中目标效应大小的研究。
Trials. 2018 Oct 10;19(1):544. doi: 10.1186/s13063-018-2886-y.
3
Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes.利用预试验为具有连续结果的干预试验设计提供信息的指南。
Clin Epidemiol. 2018 Jan 18;10:153-157. doi: 10.2147/CLEP.S146397. eCollection 2018.
4
Choosing the target difference ('effect size') for a randomised controlled trial - DELTA guidance protocol.为随机对照试验选择目标差异(“效应量”)——DELTA指南方案。
Trials. 2017 Jun 12;18(1):271. doi: 10.1186/s13063-017-1969-5.
5
Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers.确定随机对照试验主要结局的目标差异:给研究人员的指南。
Trials. 2015 Jan 15;16:12. doi: 10.1186/s13063-014-0526-8.
6
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.评估指定随机对照试验目标差值的方法:DELTA(试验中差值确定)综述。
Health Technol Assess. 2014 May;18(28):v-vi, 1-175. doi: 10.3310/hta18280.
7
A myriad of methods: calculated sample size for two proportions was dependent on the choice of sample size formula and software.多种方法:两比例的样本量计算取决于样本量公式和软件的选择。
J Clin Epidemiol. 2014 May;67(5):601-5. doi: 10.1016/j.jclinepi.2013.10.008. Epub 2014 Jan 16.
8
The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size.生活质量问卷核心 30 项(QLQ-C30)和癌症通用功能评估(FACT-G)在反应性、相对效率方面存在差异,因此需要的样本量也不同。
J Clin Epidemiol. 2014 Jan;67(1):100-7. doi: 10.1016/j.jclinepi.2013.02.019. Epub 2013 Oct 11.
9
A tutorial on sensitivity analyses in clinical trials: the what, why, when and how.临床试验中的敏感性分析教程:内容、原因、时机和方法。
BMC Med Res Methodol. 2013 Jul 16;13:92. doi: 10.1186/1471-2288-13-92.
10
The prevention and treatment of missing data in clinical trials.临床试验中缺失数据的预防与处理
N Engl J Med. 2012 Oct 4;367(14):1355-60. doi: 10.1056/NEJMsr1203730.